CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Business Acquisition, Pro Forma Net Income (Loss)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Business Acquisition, Pro Forma Net Income (Loss) of $128.19 million for the 12-month period ending 2014-12-27, per its 10-K filed 2015-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2015-02-17
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for the quarter ending 2014-12-27 was $27.17M, a 24.60% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for the quarter ending 2014-09-27 was $32.04M, a 10.10% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for the quarter ending 2014-06-28 was $35.26M, a 50.51% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for the quarter ending 2014-03-29 was $33.73M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for fiscal 2014 was $128.19M, a 30.14% increase from fiscal 2013.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for fiscal 2013 was $98.51M, a 14.67% increase from fiscal 2012.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. business acquisition, pro forma net income (loss) for fiscal 2012 was $85.90M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2014-12-27 | $27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $59.20M derived: sum of 2 quarters · filed 2015-02-17 | $94.47M derived: sum of 3 quarters · filed 2015-02-17 | $128.19M 10-K · filed 2015-02-17 |
| 2014-09-27 | $32.04M 10-Q · filed 2014-10-30 | $67.30M derived: sum of 2 quarters · filed 2014-10-30 | $101.03M 10-Q · filed 2014-10-30 | $122.83M derived: sum of 4 quarters · filed 2015-02-17 |
| 2014-06-28 | $35.26M 10-Q · filed 2014-08-07 | $65.69M 10-Q · filed 2014-08-07 | $90.80M derived: sum of 3 quarters · filed 2015-02-17 | $119.89M derived: sum of 4 quarters · filed 2015-02-17 |
| 2014-03-29 | $33.73M derived: 10-K 12 month − 3 quarters · filed 2015-02-17 | $55.53M derived: sum of 2 quarters · filed 2015-02-17 | $84.63M derived: sum of 3 quarters · filed 2015-02-17 | $108.06M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-12-28 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $50.90M derived: sum of 2 quarters · filed 2015-02-17 | $74.33M derived: sum of 3 quarters · filed 2015-02-17 | $98.51M 10-K · filed 2015-02-17 |
| 2013-09-28 | $29.10M 10-Q · filed 2014-10-30 | $52.53M derived: sum of 2 quarters · filed 2014-10-30 | $76.70M 10-Q · filed 2014-10-30 | |
| 2013-06-29 | $23.43M 10-Q · filed 2014-08-07 | $47.61M 10-Q · filed 2014-08-07 | ||
| 2012-12-29 | $85.90M 10-K · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |